Innovent Biologics (IVBXF,1801.HK) announced that the New Drug Application for TABOSUN has been approved by China's National Medical Products Administration, in combination with sintilimab as neoadjuvant treatment for stage IIB-III resectable microsatellite instability-high or mismatch repair deficient colon cancer. TABOSUN is the world's first approved CTLA-4 mAb for neoadjuvant treatment of colon cancer.
The approval is based on results from the randomized, controlled, multicenter, pivotal Phase 3 clinical trial, which evaluated the safety and efficacy of ipilimumab N01 combined with sintilimab as neoadjuvant therapy compared with direct radical surgery for MSI-H/dMMR colon cancer.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.